Celldex Ends Phase II Enrollment For Breast Cancer Candidate
Zacks Investment Research | Aug 24, 2017 05:42AM ET
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced completion of enrollment in a phase IIb study — METRIC — evaluating lead pipeline candidate glembatumumab vedotin for treating patients with metastatic triple negative breast cancers.
Shares of Celldex have underperformed the industry year to date. The stock has massively plunged 34.4% versus the industry’s 6.9% gain during the period.
METRIC is a randomized phase IIb study which enrolled a total of 327 patients with the given indication. Patients in this trial are randomized 2 to 1 to either glembatumumab vedotin or to Roche Holding (SIX:ROG) AG’s (OTC:RHHBY) breast cancer drug, Xeloda (capecitabine).
The primary endpoint of the study is progression-free survival (PFS). Top-line data from the study is expected in second-quarter 2018.
We remind investors that another phase II study on glembatumumab vedotin is currently underway on patients with metastatic melanoma as a single agent. Data from the study was presented in June, at the annual meeting of the American Society of Clinical Oncology (ASCO).
Glembatumumab vedotin performed well in the single agent setting with 11% response rate, a 52% disease control rate and a median duration of response of six months in patients, having failed three or four prior lines of therapy. The study also includes two new cohorts, a glembatumumab plus varlilumab arm and a glembatumumab plus checkpoint inhibitor arm, including either Bristol-Myers Squibb Company’s (NYSE:BMY) Opdivo or Merck & Co, Inc.’s (NYSE:MRK) Keytruda.
Besides glembatumumab vedotin, Celldex’s pipeline comprises another important candidate, varlilumab. It is being evaluated in several phase I/II combination studies across multiple types of cancer.
Zacks Rank
Celldex currently carries a Zacks Rank #3 (Hold). You can see .
One Simple Trading Idea
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing and exclusive of fees, it can turn thousands into millions of dollars.
This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today.
Get The News You Want
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.